ICVX Share Price Performance
US$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
ICVX Community Narratives
There are no narratives available yet.
Recent ICVX News & Updates
Icosavax, Inc. Key Details
Last Reported Earnings
Sep 30, 2023
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.90
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Icosavax, Inc. Competitors
Snowflake Analysis
About ICVX
- Founded
- 2017
- Employees
- 60
- CEO
- WebsiteView website
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington.
Market Insight
Market sentiment on BTC treasury companies is moving, and with volatility rising, disagreements over their future prospects are as heated as ever.
Continue reading
U.S. Market Performance
- 7 Days: 0.5%
- 3 Months: 11.7%
- 1 Year: 15.7%
- Year to Date: 10.1%
The market has been flat over the last week. More promisingly, the market is up 16% over the past year. Earnings are forecast to grow by 15% annually. Market details ›